Article
Oncology
H. Borghaei, T. -E. Ciuleanu, J. -S Lee, A. Pluzanski, R. Bernabe Caro, M. Gutierrez, Y. Ohe, M. Nishio, J. Goldman, N. Ready, D. R. Spigel, S. S. Ramalingam, L. G. Paz-Ares, J. F. Gainor, S. Ahmed, M. Reck, M. Maio, K. J. O'Byrne, A. Memaj, F. Nathan, P. Tran, M. D. Hellmann, J. R. Brahmer
Summary: First-line nivolumab plus ipilimumab treatment in advanced NSCLC can prolong survival and have significant clinical benefits, with tumor response affecting survival.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Qing Ye, Salvi Singh, Peter R. Qian, Nancy Lan Guo
Summary: There are currently no effective biomarkers to select chemotherapy, immunotherapy, and radiotherapy for treating lung cancer patients. This study identified genetic networks containing major immune-checkpoint inhibitors CD27, PD1, and PDL1, and their associated prognostic genes and proliferation genes in lung cancer tumors. A 5-gene prognostic model was developed and validated in extensive cohorts to select patients at a high risk for developing metastasis.
Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
M. Reck, T. -E. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, J. Bennouna, E. Felip, O. Juan-Vidal, A. Alexandru, H. Sakai, A. Lingua, F. Reyes, P. -J. Souquet, P. De Marchiy, C. Martin, M. Perol, A. Scherpereel, S. Lu, L. Paz-Ares, D. P. Carbone, A. Memaj, S. Marimuthu, X. Zhang, P. Tran, T. John
Summary: The updated data from the phase III CheckMate 9LA trial with a minimum 2-year follow-up show that first-line nivolumab plus ipilimumab with two cycles of chemotherapy continues to provide prolonged overall survival benefits over chemotherapy in advanced non-small-cell lung cancer patients, with manageable safety profile. Improved efficacy outcomes were observed in most subgroups with no new safety signals detected.
Article
Oncology
Bai-Wei Zhao, Fei-Yang Zhang, Yun Wang, Guo-Ming Chen, Man Nie, Zhou-Kai Zhao, Xiao-Jiang Chen, Kai-Ming Jiang, Run-Cong Nie, Ying-Bo Chen
Summary: The efficacy of LAG3-PD1 and CTLA4-PD1 inhibition in previously untreated advanced melanoma patients is similar, but LAG3-PD1 inhibition appears to have earlier survival benefits and fewer adverse events.
Article
Oncology
Szu-Chun Yang, Natalia Kunst, Cary P. Gross, Jung-Der Wang, Wu-Chou Su, Shi-Yi Wang
Summary: Based on subgroup and probabilistic analysis, researchers found that first-line N+I or N+I+chemotherapy for metastatic NSCLC patients was not cost-effective from the U.S. health care sector perspective, regardless of PD-L1 expression levels.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Huihui Jiang, Aiqun Xu, Wanli Xia, Xingyuan Xia, Pulin Li, Binbin Zhang, Ke Zhu, Sijing Zhou, Ran Wang
Summary: Through comprehensive analysis, lung cancer patients treated with immunotherapy showed better overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) compared to those receiving chemotherapy. Whether used alone or in combination, immunotherapy demonstrated more clinically meaningful survival benefits.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.
Article
Oncology
Yana G. Najjar, Dustin McCurry, Huang Lin, Yan Lin, Yan Zang, Diwakar Davar, Arivarasan Karunamurthy, Joseph J. Drabick, Rogerio I. Neves, Lisa H. Butterfield, Marc S. Ernstoff, Igor Puzanov, Joseph J. Skitzki, Jennifer Bordeaux, IlaSri B. Summit, Jehovana O. Bender, Ju Young Kim, Beiru Chen, Ghanashyam Sarikonda, Anil Pahuja, Jennifer Tsau, Zeni Alfonso, Christian Laing, James F. Pingpank, Matthew P. Holtzman, Cindy Sander, Amy Rose, Hassane M. Zarour, John M. Kirkwood, Ahmad A. Tarhini
Summary: Neoadjuvant concurrent HDI and pembrolizumab therapy showed promising clinical activity in resectable advanced melanoma patients, despite high rates of treatment discontinuation. Pathologic complete response was identified as a prognostic indicator.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Rana R. McKay, Katharina Leucht, Wanling Xie, Opeyemi Jegede, David A. Braun, Michael B. Atkins, Marc-Oliver Grimm, Toni K. Choueiri
Summary: The combination of nivolumab and ipilimumab has shown to be beneficial for a subset of RCC patients who do not respond to nivolumab alone. It is recommended that both drugs be given concurrently to improve treatment outcomes.
Article
Oncology
T. Al-Toubah, T. Halfdanarson, J. Gile, B. Morse, K. Sommerer, J. Strosberg
Summary: The combination therapy of ipilimumab and nivolumab shows modest activity in patients with high-grade neuroendocrine neoplasms who have progressed on prior cytotoxic chemotherapy.
Article
Oncology
Hugo Arasanz, Ana Isabel Bocanegra, Idoia Morilla, Joaquin Fernandez-Irigoyen, Maite Martinez-Aguillo, Lucia Teijeira, Maider Garnica, Ester Blanco, Luisa Chocarro, Karina Ausin, Miren Zuazo, Gonzalo Fernandez-Hinojal, Miriam Echaide, Leticia Fernandez-Rubio, Sergio Pineiro-Hermida, Pablo Ramos, Laura Mezquita, David Escors, Ruth Vera, Grazyna Kochan
Summary: This study investigated the role of baseline circulating low-density neutrophils (LDN) in NSCLC patients, identifying LDN as a predictive biomarker for immunotherapy resistance. Combining immunotherapy with chemotherapy can reduce LDN levels, overcome resistance, and suggest potential drug combinations for improved outcomes.
Article
Biochemistry & Molecular Biology
Farshad Nassiri, Vikas Patil, Leeor S. Yefet, Olivia Singh, Jeff Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, Mariza Daras, Timothy F. Cloughesy, Howard Colman, Priya U. Kumthekar, Clark C. Chen, Robert Aiken, Morris D. Groves, Shirley S. Ong, Rohan Ramakrishna, Michael A. Vogelbaum, Simon Khagi, Thomas Kaley, Jason M. Melear, David M. Peereboom, Analiz Rodriguez, Maxim Yankelevich, Suresh G. Nair, Vinay K. Puduvalli, Kenneth Aldape, Andrew Gao, Alvaro Lopez-Janeiro, Carlos E. de Andrea, Marta M. Alonso, Paul Boutros, Joan Robbins, Warren P. Mason, Adam M. Sonabend, Roger Stupp, Juan Fueyo, Candelaria Gomez-Manzano, Frederick F. Lang, Gelareh Zadeh
Summary: Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, were evaluated in a multicenter phase 1/2 study for the treatment of recurrent glioblastoma. The combination of intratumoral DNX-2401 followed by intravenous pembrolizumab showed notable survival benefit with an objective response rate of 10.4% and overall survival at 12 months of 52.7%. Exploratory analyses suggested potential predictors of treatment response and resistance. Overall, this combination therapy demonstrated promising results in select patients with glioblastoma.
Review
Oncology
Xiaoxiang Zhou, Zhuoran Yao, Hua Bai, Jianchun Duan, Zhijie Wang, Xin Wang, Xue Zhang, Jiachen Xu, Kailun Fei, Zhen Zhang, Fengwei Tan, Qi Xue, Shugeng Gao, Yibo Gao, Jie Wang, Jie He
Summary: This study comprehensively investigated the incidences and profiles of treatment-related adverse events in different PD-1 or PD-L1 inhibitor-based combination therapies. Results showed variations in the incidence and profiles of adverse events among different combination therapies, providing essential reference for clinicians in routine practice of cancer care.
Article
Oncology
Panpan Jiang, Ziyang Mao, Qinyang Wang, Xiaohui Jia, Luying Geng, Hong Xu, Lili Jiang, Chengcheng Yang, Min Jiao, Hui Guo
Summary: The study suggests that N-I + chemo is comparable to Pem + chemo in terms of OS and ORR, but may have inferior PFS. In terms of safety, N-I + chemo showed no significant difference compared to Pem + chemo in any grade adverse events, but demonstrated reduced toxicity in chemo-related adverse events.
FRONTIERS IN ONCOLOGY
(2021)
Article
Engineering, Biomedical
Sara Nadine, Clara R. Correia, Joao F. Mano
Summary: The study proposes the use of liquefied capsules as an immunomodulatory 3D platform to evaluate the immune response following the implantation of biomedical devices. Experimental results show that chitosan-ending capsules and the presence of MSCs promote a more regenerative polarization balance of macrophages.
ADVANCED HEALTHCARE MATERIALS
(2021)
Review
Engineering, Biomedical
Clara R. Correia, Isabel M. Bjorge, Sara Nadine, Joao F. Mano
Summary: The emerging tissue engineering strategies focus on an integrative cell-material perspective to provide biochemical, geometrical, and biophysical cues while minimizing the use of biomaterials to promote tissue healing. Through a minimalist-engineering approach, the goal is to fine-tune the spatial balance of the regenerative niche to activate the key living components during the healing process.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Engineering, Biomedical
Sara Vilabril, Sara Nadine, Catarina M. S. S. Neves, Clara R. Correia, Mara G. Freire, Joao A. P. Coutinho, Mariana B. Oliveira, Joao F. Mano
Summary: The study describes the one-step fast formation of robust polymeric capsules through interfacial complexation of oppositely charged polyelectrolytes in an all-aqueous environment, which is compatible with the encapsulation of mesenchymal stem/stromal cells (MSCs) and microcarriers. Cell aggregation and secretion over time can be tailored by providing cells with static or dynamic (bioreactor) environments.
ADVANCED HEALTHCARE MATERIALS
(2021)
Review
Oncology
Ramon Andrade Bezerra De Mello, Rafael Voscaboinik, Joao Vittor Pires Luciano, Rafaela Vilela Cremonese, Giovanna Araujo Amaral, Pedro Castelo-Branco, Georgios Antoniou
Summary: This paper provides a reliable data source on advanced non-small cell lung cancers without driver mutations and their treatment with immunotherapy. Through a review of the latest research on PD-1/PD-L1 and CTLA-4 inhibitors, the paper presents the current advancements in immunotherapy for this type of lung cancer, particularly the use of PD-1, PD-L1, and CTLA-4 inhibitors. Immunotherapy has transformed the treatment of advanced NSCLC lacking driver mutations, becoming first-line therapy with excellent results. The paper also explores the combination of cytotoxic chemotherapy, VEGF inhibitors, and immunotherapy for patients with low PDL-1 positivity tumors, showing significant improvement in overall survival and progression-free survival.
Review
Engineering, Biomedical
Sara Nadine, Ada Chung, Sibel Emir Diltemiz, Brooke Yasuda, Charles Lee, Vahid Hosseini, Solmaz Karamikamkar, Natan Roberto de Barros, Kalpana Mandal, Shailesh Advani, Benjamin Behnam Zamanian, Marvin Mecwan, Yangzhi Zhu, Mohammad Mofidfar, Mohammad Reza Zare, Joao Mano, Mehmet Remzi Dokmeci, Farshid Alambeigi, Samad Ahadian
Summary: This article reviews various microfabrication technologies used in tissue engineering and discusses their advantages, drawbacks, and areas for further research.
Review
Biotechnology & Applied Microbiology
Maryam Tavafoghi, Fatemeh Nasrollahi, Solmaz Karamikamkar, Mahboobeh Mahmoodi, Sara Nadine, Joao F. Mano, Mohammad A. Darabi, Jamileh Jahangiry, Samad Ahadian, Ali Khademhosseini
Summary: Microneedles (MNs) have been developed as minimally invasive tools for diagnostic and therapeutic applications. There is increasing interest in developing smart multifunctional MN devices for body fluid extraction, biosensing, and drug delivery. The main challenge is integrating multiple modules, such as drug carriers and biosensors, in one miniaturized MN device. Researchers have shown the feasibility of creating smart MNs using biomaterials and microscale technologies. Hydrogel-based MN devices show high potential for biomedical applications. The improvement of biomaterials knowledge and biofabrication techniques will allow the development of more effective personalized therapeutics.
BIOTECHNOLOGY AND BIOENGINEERING
(2022)
Article
Engineering, Biomedical
Sara Nadine, Ines Fernandes, Sonia G. Patricio, Clara R. Correia, Joao F. Mano
Summary: This study proposes a method to bioengineer biomimetic bone niches using immune cells, particularly macrophages. The incorporation of macrophages within the fabricated microcapsules allows for the recreation of an appropriate bone microenvironment and the development of new bone mineralized microtissues. The findings indicate the potential of using this method in bone tissue engineering and disease modeling.
ADVANCED HEALTHCARE MATERIALS
(2022)
Article
Engineering, Biomedical
Claudia S. Oliveira, Sara Nadine, Maria C. Gomes, Clara R. Correia, Joao F. Mano
Summary: This study proposes a novel method for recreating the biological complexity of living bone marrow by fabricating a human bone marrow-in-a-liquefied-capsule, allowing the encapsulated cells to move freely and self-organize. The engineered capsules partially mimic the structure, composition, and spatial organization of the native osteovascular niches in the bone marrow. This approach provides a platform for studying the components and interactions of the bone marrow niches and their regulation of homeostasis and hematopoiesis.
ACTA BIOMATERIALIA
(2022)
Review
Multidisciplinary Sciences
Sara Nadine, Ines J. Fernandes, Clara R. Correia, Joao F. Mano
Summary: To solve challenges in bone grafting, tissue engineering strategies are proposed for repairing critical-sized defects. One promising approach is the use of cartilage-mediated bone constructs, mimicking the process of endochondral ossification. This review discusses the recent biomimetic strategies and the importance of different cell types, culture conditions, and biomaterials in promoting successful bone regeneration.
Article
Oncology
Katia Roque, Rossana Ruiz, Iris Otoya-Fernandez, Jose Galarreta, Tatiana Vidaurre, Ramon Andrade de Mello, Silvia Neciosup, Luis Mas, Henry Gomez
Summary: This study retrospectively analyzed the use of telemedicine for cancer care during the COVID-19 pandemic. The results showed that telemedicine played an important role in maintaining the continuity of cancer care, and patients reported a high level of satisfaction with telemedicine.
Review
Materials Science, Biomaterials
Sara Nadine, Clara R. Correia, Joao F. Mano
Summary: Immune cells play a crucial role in bone tissue engineering strategies, and their interaction with the immune system needs to be considered. Smart hydrogels incorporating immunomodulatory factors, stem cells, and immune cells are being proposed to upgrade the development of innovative engineered strategies.
BIOMATERIALS ADVANCES
(2022)
Meeting Abstract
Cell & Tissue Engineering
Sara Nadine, Clara R. Correia, Joao F. Mano
TISSUE ENGINEERING PART A
(2022)
Meeting Abstract
Cell & Tissue Engineering
Ana Sofia Silva, Lucia Ferreira Santos, Ana Lucia Cunha, Sara Nadine, Clara Rosa Correia, Joao Filipe Mano
TISSUE ENGINEERING PART A
(2022)
Meeting Abstract
Cell & Tissue Engineering
Sara Vilabril, Sara Nadine, Catarina Neves, Clara Correia, Mara Freire, Joao Coutinho, Mariana Oliveira, Joao Mano
TISSUE ENGINEERING PART A
(2022)
Article
Oncology
Helder Almeida-Lousada, Andre Mestre, Sara Ramalhete, Aryeh J. Price, Ramon Andrade de Mello, Ana D. Marreiros, Ricardo Pires das Neves, Pedro Castelo-Branco
Summary: Colorectal cancer plays a significant role in cancer incidence and mortality worldwide, requiring improved screening methods for early detection and patient management. The three pillars of CRC screening include endoscopy, radiological imaging, and molecular assays, with biomarker-based screening methods showing promising advantages for the future.
